These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24636375)

  • 1. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
    Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Jansen JP; Trikalinos T; Cappelleri JC; Daw J; Andes S; Eldessouki R; Salanti G
    Value Health; 2014 Mar; 17(2):157-73. PubMed ID: 24636374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Berger ML; Martin BC; Husereau D; Worley K; Allen JD; Yang W; Quon NC; Mullins CD; Kahler KH; Crown W
    Value Health; 2014 Mar; 17(2):143-56. PubMed ID: 24636373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
    Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
    Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
    Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Value Health; 2012; 15(6):835-42. PubMed ID: 22999133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
    Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
    Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
    Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
    Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.